T1	Participants 17 28	neoadjuvant
T2	Participants 138 183	hormone receptor-positive (HR+) breast cancer
T3	Participants 412 475	HR+ breast cancer in both the neoadjuvant and adjuvant settings
T4	Participants 600 613	multinational
T5	Participants 636 720	postmenopausal women with HR+ breast cancer ineligible for breast-conserving surgery
T6	Participants 1923 1983	postmenopausal women with HR+ locally advanced breast cancer
